- Display 15 Products per page
Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...Published: January 1, 2003 | Price: $2,500.00 – $5,000.00
Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike...Published: April 1, 2005 | Price: $2,500.00 – $5,000.00
In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents). In addition...Published: May 1, 2005 | Price: $2,500.00 – $5,000.00
For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency. In addition to the scientific and technical challenges of new antibiotic development, there are significant...Published: June 1, 2005 | Price: $2,500.00 – $5,000.00
This volume of Kalorama Information’s World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides an An overview Description of products on the market Description of products in development Market estimates and forecasts through 2009 Market segmentation by infection type Market segmentation by geographic region Market share of leading...Published: August 1, 2005 | Price: $2,500.00 – $5,000.00
This market briefing concentrates on the U.S. market for medical nutritional support—in particular, the enteral and parenteral foods. The continuing development of equipment, medical foods, and feeding procedures that secure the nutrition of critically ill patents has greatly improved recovery and survival in select populations. Advances in the effectiveness and safety of nutritional procedures and techniques have evolved from steady improvements, including the use of antibiotic materials, biosensors, wireless communications, and more efficient pumps and controllers. These new developments have...Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: February 1, 2007 | Price: $2,500.00 – $7,990.00
With over 6,160 individual data points reflecting useful market data, Kalorama's Cancer Therapeutics: The Worldwide Market, 2nd Edition is the most comprehensive and recent information available on the five key cancer therapy and treatment markets in a syndicated market research report, including the following areas: Chemotherapy, including -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...Published: July 1, 2007 | Price: $2,500.00 – $5,000.00
An understanding of the market for anesthesia could be worthwhile to any pharmaceutical marketer and any equity company investing or consulting in this area. Anesthesia markets are in one sense simple: growth in these drugs are correlated to prevalence and incidence in disease, and the resulting increase in procedure volumes. But as this market continues to grow, increased competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas of the world. New...Published: December 1, 2010 | Price: $2,500.00 – $5,000.00
Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience. Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug...Published: February 1, 2012 | Price: $2,500.00 – $5,000.00
Vaccines are among the top revenue earners in recent years, and in some cases have assisted major pharmaceutical companies to revenue growth. But this is not without some trade-offs. Vaccines involve a complex production process. Is vaccine-making profitable? How much is the industry spending? How much is handed off to other companies and how much is made by the branded manufacturers? How many doses are produced by the industry? These are the type of questions that Kalorama Information has taken...Published: August 3, 2012 | Price: $2,500.00 – $5,000.00
What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the...Published: June 13, 2013 | Price: $2,500.00 – $5,000.00
In recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S., Europe, Japan and globally. With over 400 pages of market analysis and over 120 figures and tables, the report provides in-depth coverage of key competitors and important trends and challenges for makers of orphan drug treatments. Osteoporosis,...